Subcutaneous Levetiracetam Application Sustains Therapeutic Drug Levels
We report on a patient suffering from seizures caused by cerebral metastases of adenocarcinoma of the lung. Initially, the patient was treated effectively with oral levetiracetam. As the disease progressed, oral intake was no longer possible. Since levetiracetam had controlled the patient's sei...
Format: | Article |
---|---|
Language: | English |
Published: |
Mary Ann Liebert
2021-05-01
|
Series: | Palliative Medicine Reports |
Online Access: | https://www.liebertpub.com/doi/full/10.1089/PMR.2020.0119 |
Similar Items
-
Experience of using subcutaneous levetiracetam in palliative patients
by: G. Más-Sesé, et al.
Published: (2021-07-01) -
Therapeutic Drug Monitoring of Levetiracetam in Select Populations
by: Dael Jarvie, et al.
Published: (2018-08-01) -
Levetiracetam Therapeutic Drug Monitoring in a Large Cohort of Korean Epileptic Patients
by: Changhee Ha, et al.
Published: (2021-08-01) -
Therapeutic levetiracetam monitoring during pregnancy: “mind the gap”
by: Maya Berlin, et al.
Published: (2019-05-01) -
Review: Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited
by: Rainer Surges, et al.
Published: (2008-07-01)